Adial Pharmaceuticals Inc
$ 3.98
-17.08%
07 Aug - close price
- Market Cap 10,504,700 USD
- Current Price $ 3.98
- High / Low $ 4.87 / 3.70
- Stock P/E N/A
- Book Value 2.46
- EPS -5.86
- Next Earning Report 2026-08-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.09 %
- ROE -2.66 %
- 52 Week High 10.75
- 52 Week Low 1.31
About
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for the treatment or prevention of addictions and related disorders. The company is headquartered in Charlottesville, Virginia.
Analyst Target Price
$8.33
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-08 | 2026-03-10 | 2025-11-13 | 2025-08-13 | 2025-05-14 | 2025-03-04 | 2024-11-13 | 2024-08-13 | 2024-04-04 | 2024-02-20 | 2023-11-14 | 2023-08-21 |
| Reported EPS | -1.48 | -11.48 | -2 | -4.5 | -8.5 | -0.15 | -9.5 | -14.75 | -9.25 | -1.35 | -28.5 | -33.25 |
| Estimated EPS | -2.25 | -2.13 | -3.5 | -5.5 | -12.37 | -0.33 | -11 | -9.75 | -19 | -0.76 | -28.37 | -56.25 |
| Surprise | 0.77 | -9.35 | 1.5 | 1 | 3.87 | 0.18 | 1.5 | -5 | 9.75 | -0.59 | -0.13 | 23 |
| Surprise Percentage | 34.2222% | -438.9671% | 42.8571% | 18.1818% | 31.2854% | 54.5455% | 13.6364% | -51.2821% | 51.3158% | -77.6316% | -0.4582% | 40.8889% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-12 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADIL
2026-08-03 23:11:30
A. G. P. has initiated coverage on Adial Pharmaceuticals (ADIL.US) with a "Buy" rating. The firm has set a target price of $11 for the stock. This initiation suggests a positive outlook on Adial Pharmaceuticals' future performance by A. G. P.
2026-08-03 11:08:00
Alliance Global Partners has initiated coverage on ADIAL Pharmaceuticals Inc. with a "Buy" rating and a price target of $11. This news was reported by Reuters, indicating a positive outlook from the analytical firm for the pharmaceutical company.
2026-08-03 11:08:00
Alliance Global Partners has initiated coverage on Adial Pharmaceuticals Inc. with a "Buy" rating. The firm has set a price target of $11 for the company's stock. This news indicates a positive outlook from Alliance Global Partners for Adial Pharmaceuticals.
2026-07-30 00:02:32
This article provides a technical analysis of Adial Pharmaceuticals Inc (ADIL), covering its support, resistance, indicators, and moving averages. According to the analysis, various technical indicators show a mixed signal with some buy and neutral recommendations, while moving averages predominantly signal 'Buy'. The overall technical signal for ADIL is currently neutral.
2026-07-29 19:40:11
This article details the shareholder structure of Adial Pharmaceuticals Inc (ADIL), listing major individual and institutional holders. It provides a breakdown of shareholder types and traces institutional shareholding changes over several quarters, highlighting key investors and their changes in shareholding.
2026-07-27 22:42:30
The article discusses the revenue breakdown of Adial Pharmaceuticals Inc (ADIL), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. Despite the lack of specific breakdown details, the article provides current stock information, including the stock price and market capitalization for ADIL.
